ProfileGDS5678 / 1424258_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 78% 78% 78% 77% 78% 79% 77% 78% 77% 77% 78% 77% 78% 78% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.3442278
GSM967853U87-EV human glioblastoma xenograft - Control 25.3575278
GSM967854U87-EV human glioblastoma xenograft - Control 35.3293278
GSM967855U87-EV human glioblastoma xenograft - Control 45.3734177
GSM967856U87-EV human glioblastoma xenograft - Control 55.3738478
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.3338879
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.098477
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.317778
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.3140477
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.335277
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.3299378
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.3292177
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.3343178
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.3237278